Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review).

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Polyphenol‑based interventions in breast cancer: Signaling pathways, molecular mechanisms and translational therapeutic strategies (Review).
Συγγραφείς:	Zeng J; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Hu J; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Ma Z; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Zhu S; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Lv X; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Zhang L; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Shen M; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China., Li T; Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.
Πηγή:	Oncology reports [Oncol Rep] 2026 Oct; Vol. 56 (4). Date of Electronic Publication: 2026 Aug 14.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE
Imprint Name(s):	Publication: <2003->: Athens : D.A. Spandidos Original Publication: [Athens, Greece] : National Hellenic Research Foundation, 1994-
Ιατρικοί όροι (MeSH):	Polyphenols/therapeutic use , Polyphenols/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology, Signal Transduction/drug effects ; Humans ; Female ; Animals ; Translational Research, Biomedical
Περίληψη:	Breast cancer (BC) comprises multiple molecular subtypes with distinct epidemiological, biological and therapeutic features. Although advances in diagnosis and systemic therapy have improved patient outcomes, therapeutic resistance, treatment‑related toxicity and disease recurrence remain major clinical challenges. Growing evidence suggests that plant‑derived polyphenols may influence BC progression through multiple biological mechanisms. These compounds can inhibit tumor‑cell proliferation, migration, angiogenesis, inflammation, epithelial‑mesenchymal transition and metastasis, while promoting apoptosis, autophagy, cell‑cycle arrest and tumor‑suppressive responses. Mechanistically, polyphenols may regulate several interconnected signaling pathways involved in BC development and progression, including PI3K/AKT/mTOR, p53, NF‑κB, STAT3, Wnt/β‑catenin and MAPK signaling. In addition to their direct effects on tumor cells, polyphenols may interact with the gut microbiome, which in turn influences polyphenol metabolism, estrogen homeostasis, immune regulation, inflammation and bioavailability. Probiotics, prebiotics and microbiota‑derived metabolites may further influence this polyphenol‑gut microbiome‑BC axis. Polyphenols have also been explored as adjuvant or supportive agents in combination with chemotherapy, endocrine therapy and radiotherapy, as well as in novel delivery systems designed to improve their bioavailability and therapeutic efficacy. However, most current evidence remains preclinical. Well‑designed clinical trials are therefore needed to define the optimal formulations, doses, safety profiles, pharmacokinetics and therapeutic relevance of polyphenol‑based interventions in BC.
References:	Int J Mol Sci. 2026 Mar 25;27(7):. (PMID: 41977169) Front Oncol. 2025 Jun 17;15:1617410. (PMID: 40599853) Clin Cancer Res. 2024 Mar 1;30(5):965-974. (PMID: 37847493) Drug Des Devel Ther. 2021 Jan 12;15:125-140. (PMID: 33469265) Cell Host Microbe. 2024 Jun 12;32(6):925-944.e10. (PMID: 38754417) Life Sci. 2021 Sep 1;280:119729. (PMID: 34146553) Photochem Photobiol Sci. 2025 Mar;24(3):451-465. (PMID: 40095354) Foods. 2021 Dec 20;10(12):. (PMID: 34945706) Mol Nutr Food Res. 2025 Aug;69(16):e70055. (PMID: 40190185) J Mater Chem B. 2026 Mar 11;14(10):3239-3254. (PMID: 41738466) Molecules. 2022 May 20;27(10):. (PMID: 35630763) Molecules. 2023 Mar 10;28(6):. (PMID: 36985507) Oncol Rep. 2021 Feb;45(2):717-727. (PMID: 33416150) Chem Biol Interact. 2026 Jan 5;423:111825. (PMID: 41232639) Pharmaceutics. 2022 Feb 15;14(2):. (PMID: 35214154) Int J Biol Macromol. 2021 Aug 31;185:134-152. (PMID: 34147524) Clin Imaging. 2026 Apr;132:110741. (PMID: 41671902) J Biochem Mol Toxicol. 2021 Feb;35(2):e22642. (PMID: 33058431) Arch Pharm (Weinheim). 2024 Oct;357(10):e2400261. (PMID: 38943449) Int Immunopharmacol. 2020 Jul;84:106535. (PMID: 32361569) Med Oncol. 2025 Dec 26;43(2):94. (PMID: 41452530) Sci Rep. 2024 Jan 17;14(1):1510. (PMID: 38233443) Life Sci. 2021 Jan 15;265:118787. (PMID: 33249095) Food Res Int. 2022 Nov;161:111800. (PMID: 36192946) Med Oncol. 2026 May 12;43(6):. (PMID: 42118362) Nanotheranostics. 2021 Jan 1;5(1):113-124. (PMID: 33391978) J Anim Sci. 2025 Jan 04;103:. (PMID: 40036370) Oncol Rep. 2024 Aug;52(2):. (PMID: 38940326) Discov Oncol. 2025 Aug 14;16(1):1554. (PMID: 40813507) Phytomedicine. 2026 Mar;152:157819. (PMID: 41638057) Fitoterapia. 2024 Jun;175:105927. (PMID: 38548028) Int J Mol Cell Med. 2021 Winter;10(1):11-22. (PMID: 34268250) Pharmaceuticals (Basel). 2026 Mar 30;19(4):. (PMID: 42075806) Appl Biochem Biotechnol. 2023 Apr;195(4):2687-2708. (PMID: 35262883) Cell Biochem Funct. 2024 Dec;42(8):e70014. (PMID: 39529484) Sci Rep. 2025 May 19;15(1):17279. (PMID: 40389522) Signal Transduct Target Ther. 2025 Feb 19;10(1):49. (PMID: 39966355) Cancer Invest. 2025 Mar;43(3):173-182. (PMID: 40145664) Bioorg Chem. 2024 Apr;145:107178. (PMID: 38359708) Food Res Int. 2024 Sep;192:114778. (PMID: 39147466) Support Care Cancer. 2020 Jul;28(7):3303-3311. (PMID: 31758326) Phytomedicine. 2020 May 23;76:153243. (PMID: 32535482) Int J Pharm. 2023 Oct 15;645:123392. (PMID: 37683979) Phytomedicine. 2020 Apr 18;70:153218. (PMID: 32335356) J Pharmacol Exp Ther. 2023 Feb;384(2):254-264. (PMID: 36456194) Breast Cancer Res Treat. 2024 May;205(1):61-73. (PMID: 38280052) J Toxicol Environ Health A. 2023 Nov 17;86(22):833-845. (PMID: 37668343) Biochem Biophys Res Commun. 2025 Jul 8;769:151942. (PMID: 40359763) Food Funct. 2024 May 7;15(9):4763-4772. (PMID: 38590256) Breast Cancer Res. 2024 Oct 25;26(1):147. (PMID: 39456028) J Environ Pathol Toxicol Oncol. 2022;41(3):33-43. (PMID: 35993954) J Pharm Pharmacol. 2024 May 3;76(5):499-513. (PMID: 37971302) Adv Mater. 2026 May;38(26):e18631. (PMID: 41934190) Mediators Inflamm. 2022 Jan 29;2022:2567150. (PMID: 35132306) Int Immunopharmacol. 2024 May 30;133:112069. (PMID: 38643710) Food Chem. 2024 May 15;440:138240. (PMID: 38150907) Int J Mol Sci. 2025 Jan 14;26(2):. (PMID: 39859369) Front Immunol. 2024 Mar 27;15:1366197. (PMID: 38601156) Int J Mol Sci. 2021 Sep 01;22(17):. (PMID: 34502426) Biochem Pharmacol. 2021 Oct;192:114717. (PMID: 34352281) Nutrients. 2021 Nov 04;13(11):. (PMID: 34836197) Mol Cell Biochem. 2022 Apr;477(4):1281-1293. (PMID: 35129780) Crit Rev Oncol Hematol. 2025 Nov;215:104879. (PMID: 40783076) BMC Complement Med Ther. 2024 Sep 4;24(1):329. (PMID: 39232773) Nanoscale. 2025 Feb 27;17(9):5033-5055. (PMID: 40013710) Clin Nutr ESPEN. 2022 Dec;52:158-168. (PMID: 36513449) Probiotics Antimicrob Proteins. 2024 Jun;16(3):829-844. (PMID: 37162668) Heliyon. 2024 May 24;10(11):e31925. (PMID: 38841445) Biomedicines. 2025 Apr 18;13(4):. (PMID: 40299687) Food Chem. 2024 Nov 15;458:140262. (PMID: 38944925) Phytomedicine. 2024 Jul 25;130:155560. (PMID: 38815404) ACS Nano. 2024 May 21;18(20):12917-12932. (PMID: 38720520) Diagn Pathol. 2024 Feb 16;19(1):35. (PMID: 38365810) Cell Biochem Biophys. 2025 Jun;83(2):2533-2546. (PMID: 39760839) Nutrients. 2021 Jan 19;13(1):. (PMID: 33477894) Mol Biol Rep. 2021 Dec;48(12):7733-7742. (PMID: 34637097) Heliyon. 2023 Nov 27;9(12):e22892. (PMID: 38058440) Breast Cancer Res Treat. 2020 Nov;184(1):107-113. (PMID: 32803636) Phytother Res. 2025 Nov;39(11):5006-5024. (PMID: 40898993) J Agric Food Chem. 2021 Dec 15;69(49):14849-14855. (PMID: 34870993) J Proteome Res. 2025 Apr 04;24(4):2096-2111. (PMID: 40108892) Mol Pharm. 2020 Apr 6;17(4):1415-1427. (PMID: 32159961) J Oncol Pharm Pract. 2025 Sep;31(6):965-976. (PMID: 39110237) Talanta. 2024 Jun 1;273:125938. (PMID: 38503125) Curr Nutr Rep. 2023 Mar;12(1):83-97. (PMID: 36746877) Crit Rev Food Sci Nutr. 2020;60(4):626-659. (PMID: 30614249) Mol Nutr Food Res. 2021 Jun;65(12):e2100163. (PMID: 33939887) Nutrients. 2021 Dec 28;14(1):. (PMID: 35011012) CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. (PMID: 39352042) Nutr J. 2018 Feb 27;17(1):34. (PMID: 29486772) Health Sci Rep. 2024 Sep 16;7(9):e70052. (PMID: 39286738) Mol Med Rep. 2020 Dec;22(6):4868-4876. (PMID: 33173974) Nat Commun. 2026 May 13;17(1):. (PMID: 42129171) Biochem Biophys Res Commun. 2024 Dec 20;739:150972. (PMID: 39541924) Int J Mol Sci. 2023 Nov 05;24(21):. (PMID: 37958959) Nutrients. 2023 Jan 06;15(2):. (PMID: 36678170) Gut Microbes. 2023 Jan-Dec;15(1):2236749. (PMID: 37559394) Acta Pharm Sin B. 2022 Feb;12(2):907-923. (PMID: 35256954) Nutrients. 2020 Mar 13;12(3):. (PMID: 32183060) Cancer Cell Int. 2026 Feb 12;26(1):. (PMID: 41680875) J Clin Oncol. 2020 May 1;38(13):1419-1428. (PMID: 32031879) J Colloid Interface Sci. 2024 Dec 15;676:974-988. (PMID: 39068841) Clin Nutr. 2021 Apr;40(4):2068-2077. (PMID: 33051045)
Contributed Indexing:	Keywords: adjuvant therapy; breast cancer; drug delivery; gut microbiome; polyphenols; signaling pathways
Substance Nomenclature:	0 (Polyphenols)
Entry Date(s):	Date Created: 20260814 Date Completed: 20260814 Latest Revision: 20260907
Update Code:	20260907
PubMed Central ID:	PMC13488138
DOI:	10.3892/or.2026.9176
PMID:	42596834
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1791-2431
DOI:	10.3892/or.2026.9176